Poster: Secondary Outcomes from a Phase 2, Double-Blind, Placebo-Controlled Signal-Detection, Proof-of-Concept Study of Pitolisant in Prader-Willi Syndrome The Phase 2 clinical trial was a randomized, ...
A multicancer early detection (MCED) test was developed and validated in the case-control Circulating Cell-free Genome Atlas (CCGA) study (ClinicalTrials.gov identifier: NCT02889978). Previous ...
Analysis of Patient Reported Outcomes From PATHFINDER Indicate Minimal Patient Distress Associated with Multi-Cancer Early Detection Testing MENLO PARK, Calif., Jan. 13, 2025 /PRNewswire/ -- GRAIL, ...
At AACR 2026, Abbott presented data on Cancerguard, a multi-biomarker blood-based MCED test that combines methylation and ...
Experts discuss the growing role of early detection and predictive strategies in managing arrhythmias—particularly atrial fibrillation—highlighting the impact of wearable technology, challenges in ...
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results